Neoadjuvant therapy is extensively utilized in the treatment of breast cancer, particularly in cases of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple-negative breast cancer (1, 2). Here, ERBB2 is linked to triple-negative breast carcinoma.